Neuromyelitis optica after Japanese encephalitis vaccination.
Furukawa
Y
Y
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Komai
K
K
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Yamada
M
M
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D022321:Japanese Encephalitis Vaccines / Q000009:adverse effects*; D008297:Male; D009471:Neuromyelitis Optica / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D014611:Vaccination / Q000009:adverse effects*
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D022321:Japanese Encephalitis Vaccines
Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 2000; 18: 2963-2969.
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis. Clinical, neuroimaging and immunogenetic studies. Brain 1999; 122: 1689-1696.
Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370: 1847-1853.